Brain Trust Bio

Executive Summary

Brain Trust Bio is a San Francisco-based drug delivery company focused on overcoming the blood-brain barrier to enable therapeutics for central nervous system (CNS) disorders. Founded in 2018, the company is developing a proprietary platform designed to efficiently transport large molecules, such as antibodies and gene therapies, into the brain. This approach addresses a critical bottleneck in CNS drug development, where over 98% of small molecules and nearly all large biologics fail to cross the blood-brain barrier. By leveraging novel delivery mechanisms, Brain Trust Bio aims to unlock treatments for conditions like Alzheimer's, Parkinson's, and brain tumors, representing a significant unmet medical need. The company is currently at an early stage, with limited public information on funding or partnerships. However, its technology has the potential to be a platform play, licensing delivery capabilities to multiple pharmaceutical partners. The CNS drug delivery market is projected to exceed $10 billion by 2030, driven by aging populations and increasing prevalence of neurological diseases. While Brain Trust Bio faces risks common to early-stage biotechs—including scientific validation, funding, and competition—its focused approach and the clear clinical need position it as a compelling opportunity for investors seeking exposure to innovative drug delivery technologies. Key near-term milestones will be critical in assessing the platform's viability and commercial potential.

Upcoming Catalysts (preview)

• Q3 2026Series A financing announcement to support preclinical development60% success
• Q3 2026Publication of in vivo proof-of-concept data for lead delivery candidate50% success
• TBDPotential partnership or licensing deal with a CNS-focused pharma company30% success